NCT05782361 2025-08-20POTENTInstitute of Cancer Research, United KingdomPhase 1 Recruiting19 enrolled
NCT05120960 2024-04-17A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain TumorsM.D. Anderson Cancer CenterPhase 1 Withdrawn
NCT03492437 2023-08-07Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran EtexilateMerck KGaA, Darmstadt, GermanyPhase 1 Completed20 enrolled 14 charts
NCT01014936 2022-08-24First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid TumorsEMD SeronoPhase 1 Completed149 enrolled 41 charts